A Phase 1 Trial of Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 08 Nov 2018 Status changed from active, no longer recruiting to completed.
- 09 May 2018 Planned End Date changed from 1 Oct 2018 to 1 Oct 2019.
- 09 May 2018 Planned primary completion date changed from 1 Oct 2018 to 1 Oct 2019.